P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY

• H Einsele,
• AD Cohen,
• M Delforge,
• J Hillengass,
• H Goldschmidt,
• K Weisel,
• M-S Raab,
• C Scheid,
• JM Schecter,
• KC De Braganca,
• H Varsos,
• T-M Yeh,
• L Wang,
• M Vogel,
• C Corsale,
• M Akram,
• L Pacaud,
• T Nesheiwat,
• M Agha,
• YC Cohen

Affiliations

H Einsele

1 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II

AD Cohen

2 Abramson Cancer Center, University of Pennsylvania

M Delforge

3 University Hospitals (UZ) Leuven

J Hillengass

4 Roswell Park Comprehensive Cancer Center

H Goldschmidt

5 Department of Internal Medicine, University Hospital Heidelberg and National Center of Tumor Diseases

K Weisel

6 University Medical Center Hamburg-Eppendorf

M-S Raab

7 University Hospital Heidelberg, and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center

C Scheid

8 Department of Internal Medicine, University Hospital of Cologne

JM Schecter

9 Janssen Research & Development

KC De Braganca

9 Janssen Research & Development

H Varsos

9 Janssen Research & Development

T-M Yeh

9 Janssen Research & Development

L Wang

9 Janssen Research & Development

M Vogel

10 Janssen Global Services, LLC

C Corsale

10 Janssen Global Services, LLC

M Akram

11 Legend Biotech USA

L Pacaud

11 Legend Biotech USA

T Nesheiwat

11 Legend Biotech USA

M Agha

12 UPMC Hillman Cancer Center

YC Cohen

13 Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University